Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Sanofi | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Sanofi

Loss of $205 million to generic competition in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi

2Q Revenues: $11.2 billion (flat)

2Q Earnings: $1.5 billion (flat)

YTD Revenues: $21.9 billion (-6%)

YTD Earnings: $3.9 billion (+15%)

Comments: Pharmaceutical sales were flat at $9.4 billion. Sales lost to generic competition were $205.0 million in the quarter (Lovenox, Xatral and Taxotere in the U.S., and Taxotere, Plavix and Aprovel in the EU). Eloxatin sales were up 36% to $471.6 million. Diabetes revenue was up 14% driven by Lantus sales, up 17% to $1.5 billion. Vaccines sales were $984.7 million in the quarter, up 3%. Genzyme sales (Cerezyme, Myozyme, Fabrazyme, and Other Rare Disease products) were $545.8 million, up 9%. Emerging Markets sales were $3.5 billion, up 10%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters